Quinolone hybrids and their anti-cancer activities: An overview
- Eur J Med Chem. 2019 Mar 1:165:59-79. doi: 10.1016/j.ejmech.2019.01.017.
- 1. Academy of Advanced Interdisciplinary Studies, Qilu University of Technology (Shandong Academy of Sciences), Jinan, PR China; School of Chemistry and Pharmaceutical Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, PR China; Department of Medical Imaging, Jinling Hospital, Medical School of Nanjing University, Nanjing, PR China. Electronic address: [email protected].
- 2. Academy of Advanced Interdisciplinary Studies, Qilu University of Technology (Shandong Academy of Sciences), Jinan, PR China.
- 3. State Key Laboratory of Biobased Material and Green Papermaking (LBMP), Qilu University of Technology (Shandong Academy of Sciences), Jinan, PR China.
- 4. Academy of Advanced Interdisciplinary Studies, Qilu University of Technology (Shandong Academy of Sciences), Jinan, PR China; School of Chemistry and Pharmaceutical Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, PR China. Electronic address: [email protected].
The global pandemic of drug-sensitive cancers and the increasing threat from drug-resistant cancers make an urgent need to develop more effective anti-cancer candidates. Quinolone derivatives possess promising anti-cancer activity, and some of them have already been approved to treat cancers or under clinical trials. Hybridization of Quinolone with Other anti-cancer pharmacophores may provide more efficient anti-cancer candidates, so Quinolone hybrids worth to be investigated. In this review, the recent advances in the development of novel Quinolone hybrids as potential anti-cancer agents are highlighted, and the structure-activity relationship is also discussed to provide an insight for further development of more active Quinolone hybrids.